SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 136, Issue , 2018, Pages 23-31

  d'Emden, Michael ^a   Amerena, John ^b   Deed, Gary ^c   Pollock, Carol ^d   Cooper, Mark E ^e  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b GEELONG HOSPITAL   (Australia)

^c Mediwell Medical Clinic   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Cardiovascular risk reduction; Empagliflozin; Glycaemic control; Improved renal outcomes; Type 2 diabetes mellitus

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; FRACTURE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LEG AMPUTATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PATIENT CARE; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; UROGENITAL TRACT INFECTION; WEIGHT REDUCTION; ANTAGONISTS AND INHIBITORS; BLOOD; PATHOLOGY; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85037681382     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2017.11.023     Document Type: Review

References (61)

1. Gore, M.O., McGuire, D.K., Lingvay, I., Rosenstock, J., Predicting cardiovascular risk in type 2 diabetes: the heterogeneity challenges. Curr Cardiol Rep, 17, 2015, 607.
2. Sarwar, N., Gao, P., Seshasai, S.R., Gobin, R., Kaptoge, S., Di Angelantonio, E., et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375 (2010), 2215–2222.
3. Royal Australian College of General Practitioners and Diabetes Australia. General practice management of type 2 diabetes 2016–2018. 2016. Available at: < http://wwwracgporgau/your-practice/guidelines/diabetes/> [accessed 6 Dec 2016].
4. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
5. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
6. Heerspink, H.J., Perkins, B.A., Fitchett, D.H., Husain, M., Cherney, D.Z., Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
7. 2 inhibition in diabetes. Diabetes Metab 40 (2014), S17–S22.
8. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V., Parving, H.H., Pedersen, O., Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003), 383–393.
9. Hansson, L., Zanchetti, A., Carruthers, S.G., Dahlof, B., Elmfeldt, D., Julius, S., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998), 1755–1762.
10. Collins, R., Armitage, J., Parish, S., Sleigh, P., Peto, R., MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003), 2005–2016.
11. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370 (2007), 829–840.
12. Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000), 145–153.
13. de Boer, I.H., Bangalore, S., Benetos, A., Davis, A.M., Michos, E.D., Muntner, P., et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care 40 (2017), 1273–1284.
14. Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., et al. Policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes – 2015 interim update. Can J Diabetes 39 (2015), 250–252.
15. Ryden, L., Grant, P.J., Anker, S.D., Berne, C., Cosentino, F., Danchin, N., et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34 (2013), 3035–3087.
16. Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
17. Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
18. Turner, R.C., Millns, H., Neil, H.A., Stratton, I.M., Manley, S.E., Matthews, D.R., et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316 (1998), 823–828.
19. Selvin, E., Coresh, J., Golden, S.H., Brancati, F.L., Folsom, A.R., Steffes, M.W., Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165 (2005), 1910–1916.
20. Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P.D., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009), 129–139.
21. Gerstein, H.C., Miller, M.E., Genuth, S., Ismail-Beigi, F., Buse, J.B., Goff, D.C. Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364 (2011), 818–828.
22. Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008), 2560–2572.
23. UK Prospective Diabetes Study, UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet 352 (1998), 837–853.
24. Turnbull, F.M., Abraira, C., Anderson, R.J., Byington, R.P., Chalmers, J.P., Duckworth, W.C., et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52 (2009), 2288–2298.
25. Perkovic, V., Heerspink, H.L., Chalmers, J., Woodward, M., Jun, M., Li, Q., et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 83 (2013), 517–523.
26. Deed, G., Barlow, J., Kuo, I., Early and tight glycaemic control – the key to managing type 2 diabetes. Aust Fam Phys 41 (2012), 681–684.
27. Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
28. Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
29. White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
30. Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 373 (2015), 232–242.
31. Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.
32. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
33. Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
34. Holman, R.R., Bethel, M.A., Mentz, R.J., Thompson, V.P., Lokhnygina, Y., Buse, J.B., et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377 (2017), 1228–1239.
35. Nauck, M.A., Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther 8 (2014), 1335–1380.
36. Kosiborod, M., Cavender, M.A., Fu, A.Z., Wilding, J.P., Khunti, K., Holl, R.W., et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study. Circulation 136 (2017), 249–259.
37. Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
38. Birkeland, K.I., Jorgensen, M.E., Carstensen, B., Persson, F., Gulseth, H.L., Thuresson, M., et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 5 (2017), 709–717.
39. Persson F, Nystrom T, Jorgensen ME, Carstensen B, Gulseth HL, Thuresson M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study. Diabetes Obes Metab. 2017 [Epub ahead of print].
40. Toulis, K.A., Hanif, W., Saravanan, P., Willis, B.H., Marshall, T., Kumarendran, B., et al. All-cause mortality in patients with diabetes under glucagon-like peptide-1 agonists: a population-based, open cohort study. Diabetes Metab 43 (2017), 211–216.
41. Barnett, A.H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H.J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
42. Kohler S, Kaspers S, Salsali A, Zeller C, Woerle HJ. Effect of empagliflozin on bone fractures in patients with type 2 diabetes. Diabetes. 2016;65(Suppl. 1A):LB34–5.
43. Kaku, K., Maegawa, H., Tanizawa, Y., Kiyosue, A., Ide, Y., Tokudome, T., et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther 5 (2014), 415–433.
44. Lavalle-Gonzalez, F.J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56 (2013), 2582–2592.
45. Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H.J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1 (2013), 208–219.
46. Schernthaner, G., Gross, J.L., Rosenstock, J., Guarisco, M., Fu, M., Yee, J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36 (2013), 2508–2515.
47. Min, S.H., Yoon, J.H., Hahn, S., Cho, Y.M., Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev, 33, 2017, e2818.
48. Ferrannini, E., Berk, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H.J., et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36 (2013), 4015–4021.
49. Boehringer Ingelheim. Jardiance (empagliflozin) product information. 2017.
50. Janssen-Cilag. Invokana (canagliflozin) product information. 2017.
51. Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschope D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2017 [Epub ahead of print].
52. Garg SK, Henry RR, Banks P, Buse JB, Davies MJ, Fulcher GR, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017 [Epub ahead of print].
53. Cherney, D., Lund, S.S., Perkins, B.A., Groop, P.H., Cooper, M.E., Kaspers, S., et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59 (2016), 1860–1870.
54. Heerspink, H.J., Johnsson, E., Gause-Nilsson, I., Cain, V.A., Sjostrom, C.D., Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab 18 (2016), 590–597.
55. Fioretto, P., Zambon, A., Rossato, M., Busetto, L., Vettor, R., SGLT2 inhibitors and the diabetic kidney. Diabetes Care 39:Suppl 2 (2016), S165–S171.
56. Kohler, S., Salsali, A., Hantel, S., Kaspers, S., Woerle, H.J., Kim, G., et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes. Clin Ther 38 (2016), 1299–1313.
57. Xiong, W., Xiao, M.Y., Zhang, M., Chang, F., Efficacy and safety of canagliflozin in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Medicine (Baltimore), 95, 2016, e5473.
58. Johnsson, K.M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S.J., List, J.F., Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27 (2013), 479–484.
59. Johnsson, K.M., Ptaszynska, A., Schmitz, B., Sugg, J., Parikh, S.J., List, J.F., Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 27 (2013), 473–478.
60. Tang, H., Zhang, X., Zhang, J., Li, Y., Del Gobbo, L.C., Zhai, S., et al. Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia 59 (2016), 2546–2551.
61. Erondu, N., Desai, M., Ways, K., Meininger, G., Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 38 (2015), 1680–1686.